A Phase II, Multicenter, Single-Arm, Open-Label Study to Evaluate the Safety and Efficacy of Single-Agent Lenalidomide (Revlimid) in Subjects With Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma.
Phase of Trial: Phase II
Latest Information Update: 03 Mar 2017
At a glance
- Drugs Lenalidomide (Primary)
- Indications T cell lymphoma
- Focus Therapeutic Use
- Acronyms EXPECT
- Sponsors Celgene Corporation
- 28 Jun 2012 Celgene International Sarl added as sponsor and lead trial centre as reported by European Clinical Trials Database record.
- 08 Nov 2010 Actual end date (1 Apr 2010) added as reported by ClinicalTrials.gov.
- 08 Nov 2010 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.